Mutation of the first ATG ORF-3 of Chicken Anemia Virus into ACG completely abolish the apoptin production by Prasetyo, Afiono Agung & Kamahora, Toshio
Journal of Biotechnology and Biodiversity, April 2010; 1(1): 3-7 
                                                                                                                                                                        ISSN: 2087-0183 
3 
 
RESEARCH 
Mutation of the first ATG ORF-3 of Chicken Anemia Virus into 
ACG completely abolish the apoptin production 
 
Afiono Agung Prasetyoa*, Toshio Kamahorab 
aDepartment of Microbiology, Faculty of Medicine, Sebelas Maret University,  Jl. Ir. Sutami 36 A, Surakarta 57126, Indone-
sia 
bDivision of Virology, Department of Microbiology and Immunology, Faculty of Medicine, Tottori University, Nishi-cho, 
Yonago City 683-8503,  Japan 
 
Received : 17 December 2009  
Accepted: 5 January 2010 
 
 
Abstract 
To test the effect of one point mutation on the first initiation codon of Chicken 
Anemia Virus (CAV) open reading frame-3 (ORF-3), an apoptin knocked out 
expressor plasmid pCLS-VP3(-) and a CAV apoptin knocked out plasmid 
pCAV/Ap(-) were constructed. In both plasmids, the first ATG in ORF-3 was 
mutated into ACG by a reversed long PCR. No apoptin detected in COS-1 cells 
transfected with pCLS-VP3(-) using western blotting and immunofluorescence 
assay, while apoptin was detected in COS-1 cells transfected with pCLS wild 
type. After released from pCAV/Ap(-), the complete genome of CAV/Ap(-) was 
ligated to form the replicative form. The apoptin production was completely 
abolished in MDCC-MSB1 cells transfected with replicative form of CAV/Ap(-). 
The apoptin production was fully regained after a reverse mutation into 
CAV/Ap(-)RM. These data shows the first evidence that mutation of the first 
ATG of ORF-3 into ACG could completely abolish the production of apoptin. 
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INTRODUCTION 
 
Chicken Anemia Virus (CAV) was first 
isolated in Japan (1). CAV causes anemia in 
newborn chicken by apoptosis of 
hemocytoblasts in the bone marrow (2). CAV 
also induces apoptosis of cortical thymocytes 
and lymphoblastoid cell lines (3). CAV is a small 
non-enveloped virus with a single-stranded 
circular DNA genome in the size of 
approximately 2.3 kb (4, 5). Currently, CAV is 
the only member of genus Gyrovirus within 
family Circoviridae. However, while 
circoviruses have ambisense genomes, CAV 
has an antisense genome. CAV also lacks the 9-
nt stem-loop structure common in Circovirus 
(4, 6, 7). 
 
The configurations of ORFs in CAV were 
similar with torque teno virus, a human virus 
found in serum from a hepatitis patient with 
the initials T.T (8). These two viruses have a 
more than 80 % similarity in a 36-nt stretch 
near the replication origin, but nucleotide 
sequences of the remaining genome show no 
apparent similarities (7, 9). Their transcription 
patterns to produce three or more spliced 
mRNAs are also similar to each other (10-12). 
 
CAV replicates via a circular double-
stranded replicative form (RF) (4). The major 
transcript of CAV is an unspliced polycistronic 
mRNA which possesses three overlapping 
ORFs, encoding VP1 (52kDa), VP2 (24kDa), 
and VP3 (14 kDa) (4, 13). The capsid of CAV 
contains only the VP1 (14). VP-2 has been 
shown to interact with VP1 and has dual 
phosphatase activities (15). VP-3, known as 
apoptin, induces apoptosis selectively in 
transformed cells but not in non-transformed 
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cells (16, 17). In point of its apoptosis activity, 
reports make progress. However, the function 
of apoptin in CAV in its replication has not 
been elucidated yet. 
 
One strategy to study the role of apoptin 
in CAV replication is by a mutagenesis study, 
i.e. by knocking out the apoptin by introducing 
one point mutation in its initiation codon. 
However, the open reading frame for apoptin 
is overlap with the open reading frame for 
VP2. Furthermore, no evidence for apoptin 
production after mutation in its first ATG has 
been ever given to the best of my knowledge. 
The present study provided the first evidence 
of the mutation of first ATG of CAV ORF-3 into 
ACG could abolish the production of apoptin. 
 
 
MATERIALS AND METHODS 
 
Cell Culture 
 
Chicken T cell transformed by Marek’s 
Disease Virus, MDCC-MSB1, were used to 
replicate CAV. Cells were subcultured twice 
weekly at 39 °C in RPMI1640 medium (Sigma, 
Stenheim, Germany) supplemented with 10 % 
fetal bovine serum (FBS, Immuno-Biological 
Laboratories, Fujioka, Japan), 2 mM glutamine, 
and 0.01 % each of penicillin and 
streptomycin. African green monkey kidney 
cell expressing SV40T antigen, COS-1, were 
used to visualize localization of apoptin and its 
mutant. Cells were subcultured twice weekly 
at 37 °C in Dulbecco’s modified Eagle medium 
supplemented with 10 % FBS, 2 mM glutamine 
and 0.01 % each of penicillin and 
streptomycin. 
 
Wild-type CAV Plasmid and Apoptin 
Knocked Out Mutants 
 
A molecular clone of the wild-type CAV 
(CAV/WT), pCAV-A2C15 (pCAV/WT) 
(Genbank AB031296), was kindly supplied by 
Dr. Yamaguchi, National Institute of Animal 
Health, Japan (18). pCAV/Ap(-), a mutant 
plasmid contains a CAV clone knocked out of 
apoptin, was constructed as described 
elsewhere (19). Briefly, a point mutation, A465TG 
to ACG, was introduced to the initiation codon 
of apoptin gene on the frame 3. The mutation 
was designed to be synonymous in VP2 on the 
frame 2. A reverse mutant, pCAV/ApRM, was 
prepared using pCAV/Ap(-) as a template, as 
described elsewhere (19). 
 
pCLS-VP3(-) 
 
Another plasmid to confirm the mutation 
result was constructed as described elsewhere 
(Prasetyo, A.A., et al, submitted for 
publication). Briefly, the chicken anemia virus 
leader sequence was cloned and inserted into 
pHM6 vector (Roche Diagnostic, Mannheim, 
Germany). The clone thus obtained, pCLS, 
driven by CMV promotor could expressed a 
wild-type apoptin in animal cells, i.e. COS-1 
cells. The initiation codon of ORF-3 was 
introduced using same strategy as above using 
pCLS as template, resulted pCLS-VP3(-), a 
apoptin knocked out plasmid. 
 
Preparation of Replicative Form (RF) DNA 
 
Each molecular clone of CAV in an amount 
of 5.0 g was digested with XbaI. After 
electrophoresis on a 1 % agarose, viral DNA 
was extracted by the gel extraction kit 
(Qiagen, Hilden, Germany), and the DNA was 
circularized by the T4 DNA ligase. DNA was 
extracted with phenol-chloroform (1:1) and 
precipitated with ethanol. The pellet was 
washed with 70 % ethanol, dried, and 
resolved in filtered TE buffer (10 mM Tris-HCl, 
pH 7.5, 1 mM EDTA). Aliquot was tested in 
agarose to confirm consistent ligation. 
 
DNA Transfection  
 
MDCC-MSB1 cells (1 x 106 cells/2 ml) in 
RPMI medium free from antibiotics were 
delivered to the 35 mm dish. The RF DNA (200 
ng) was transfected with FuGENE HD (Roche) 
according to manufacturer’s protocol. COS-1 
cells (2 x 105 cells/2 ml) in DMEM medium 
free from antibiotics were delivered to the 35 
mm dish 12 h prior of transfection. The pCLS 
and pCLS-VP3(-) (1 g each) were transfected 
with FuGENE HD. All culture was harvested at 
72 h posttransfection.  
 
Western Blot Analysis 
 
Transfected cells were lysed in 200 L of 
running buffer (0.125 M Tris-HCl pH 6.8, 10 % 
2-mercaptoethanol, 4 % SDS, 10 % sucrose, 
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0.004 % bromophenol blue) and analyzed by 
sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. Proteins were transferred 
from the gel to Immobilon-P (Millipore) with a 
dry blotting system. Transfer was performed 
in 192 mM gylcine- 25 mM Tris -20 % ethanol 
for 60 min at 60 mA/cm2. Filters were 
blocked, washed, incubated with antibodies 
and developed with ECL Western Blotting 
Detection Reagents in accordance with the 
suppliers’s protocol (Amersham Biosciences). 
A mouse anti-apoptin monoclonal antibody 
(TropBio, Australia) was used to detect 
apoptin expression.  
 
Immunofluorescence 
 
The cells (one night prior to transfection 
for COS-1 cells or at the day of transfection for 
MDCC-MSB1-cells) were delivered into 8-well 
chamber slides. Cells were transfected with 1 
g of plamid with FuGENE HD, air-dried at 48 
hours posttransfection, and fixed with 4 % 
paraformaldehyde in PBS(-) for 10 min at 
room temperature. After consecutive 
washings with PBS(-) and 0.1 % Triton X-100 
in PBS(-), the slides were blocked with 15 
L/well of 1.5 % normal sheep serum (in 
PBS(-)) at 37 °C for 30 min. The cells were 
incubated with 1/100 dilution of anti-VP3 
monoclonal antibody (TropBio, Queensland, 
Australia), and then with 1/1000 horse radix 
peroxidase anti-mouse IgG antibody 
(Ammersham), each for 60 minutes at room 
temperature. The slides were mounted with 5 
ng (5 L)/well of Vectorshield with 4’-6-
diamidino-2-phenylindole dihydrochloride 
(DAPI, Vector Laboratories, Burligame, CA), 
and observed under a inverted fluorescent 
microscope (BX60: Olympus, Tokyo, Japan). 
The specimen was thoroughly washed with 
PBS(–) between each step unless otherwise 
stated. The apoptin sublocalization was 
analyzed using ImageJ, a public domain 
analysis software. 
 
 
RESULTS AND DISCUSSION 
 
 The initiation codon for apoptin located 
+133 nucleotides downstream of the 
trascription start point (nt 333), or 107 
nucleotides downstream of the VP2 initiation 
codon. The stop codon for apoptin is located at 
nt 827 while ORF-2 is at nt-1007, therefore the 
apoptin’s ORF is overlapping with ORF for 
VP2. Although the initiation codon for apoptin 
is in not high favourable sequence context (20), 
the apoptin could expressed efficiently in 
MDCC-MSB1 infected with CAV, in MDCC-
MSB1 cells transfected with replicative form of 
CAV, or in cells transfected with an apoptin 
expression plasmid (16, 21, 22). 
 
To knock out the apoptin, a point 
mutation was introduced into its initiation 
codon. The ATG was mutated into ACG in 
order to avoid any amino acid change in the 
overlapping VP2. Two different systems were 
used for this experiment, by using the 
replicative form of CAV and the expression 
plasmid. 
 
First, the effect of mutation in apoptin 
initiation codon was tested in COS-1 cells. The 
CAV leader sequence from nt 333 until 831 
was subcloned into a vector, pHM6. The 
human cytomegalovirus immediate early 
promoter / enhancer in this vector plasmid 
could ensure the efficien and high-level 
expression of recombinant protein in 
mammalian cell lines (e.g. COS-1 cells). The 
plasmid thus obtained, pCLS, contains CAV 
leader sequence with apoptin ORF on it, 
downstream of the CMV promoter. After 
transfected with pCLS, a band in apoptin size 
was detected using Western blot (Figure I-A). 
This result consistent with previous result, 
that apoptin could be expressed from an 
apoptin expression plamid (21). The 
sublocalization of apoptin also was checked. In 
COS-1 cells, > 60% of cells expressing apoptin 
showed a nuclear dominant staining (data not 
shown), consistent with previous reports (23-
26). 
 
A B     C D 
  
 
 
    
     Figure 1. Mutation of the first initiation codon of apoptin 
could abolished apoptin production. A = pCLS ; B = pCLS-
VP3(-) ; C = Replicative form CAV/WT ; D = Replicative 
form CAV/Ap(-) reverse mutant 
 
The effect of one point mutation in 
apoptin initiation codon was first tested in 
COS-1 cells, using pCLS-VP3(-). As expected, 
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no band in apoptin size was detected using 
Western blot (Figure I-B), and no cells 
expressing apoptin was found in 
immunofluorescence detection (data not 
shown). This result indicated that mutation of 
the apoptin initiation codon from ATG into 
ACG could abolish the expression of apoptin. 
 
Next, replicative form of CAV was used to 
confirm the result. One may argue that what 
happened in COS-1 cells using apoptin 
expression plasmid may not represent the 
result in CAV replication origin. After MDCC-
MSB1 cells transfected with replicative form of 
CAV wild type (CAV/WT), a band in apoptin 
size was detected using Western blot (Figure 
I-C), and cells expressing apoptin was also 
detected using immunofluorescence assay. 
Small band detected in Western blot data may 
due of protein breakdown caused by the 
highly positively charged N-terminal region of 
apoptin. However, apoptin intracellular 
distributions could not be visualized using 
immunofluorescence assay because of scanty 
cytoplasm in floating MDCC-MSB1 cells (data 
not shown). Using pCAV/WT, an apoptin 
knocked out mutant, named as pCAV/Ap(-) 
was constructed. After released from the 
backbone plasmid, the CAV/Ap(-) genom was 
circularized and transfected into MDCC-MSB1 
cells. As expected, there was no apoptin 
detected using western blotting nor 
immunofluorescence assay (data not shown). 
To confirm the result, a reverse mutant, 
CAV/Ap(-)RM was constructed and its 
replicative form was transfected into MDCC-
MSB1 cells. As expected, apoptin could fully 
regained in this reverse mutant (Figure I-D). 
Taken together, these data indicated that one 
point mutation on apoptin initiation codon, 
from ATG into ACG, could completely abolish 
the expression of apoptin. 
 
Recently, apoptin was found inevitable for 
CAV replication (19). Apoptin is important not 
only for DNA replication but also for virus 
particle formation. No infective virus detected 
in MDCC-MSB1 cells transfected with 
replicative form of CAV/Ap(-) nor the signal 
from its DNA replication. In addition, a reverse 
mutant with the reorganized apoptin gene 
obtained from CAV/Ap(-), CAV/ApRM, 
regained full recovery in the infectious virus 
production. The data presented in this study 
strongly support the recent result about 
inevitability of apoptin for CAV replication. 
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